Drugs previously inhibiting RSV fusion in vitro (anti-F drugs) which were co-crystallized with prefusion-stabilized RSV F models (anti-F drugs) were employed for co-evolution. For that, anti-F drug *.sdf files and their corresponding crystallographic F complex *.pdb files corresponding to JNJ2408068, JNJ49153390, TMC353121, BTA9881, and BMS433771 fusion-inhibitors , were supplied to DWBEL co-evolution as 2D parents-3D cavities. The program randomly generated tens of thousands of raw-children and selected those non-toxic and best-fitting their corresponding F cavities. ADV docking of TMC353121, BTA9881, and BMS433771 confirmed thousands of non-toxic fitted-children predicting higher affinities (lower docking-scores) than their corresponding drug-parents (Figure large-open circles, inside the drug rank profiles).